A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation

Alimentary Pharmacology and Therapeutics

Volumn 16, Issue 11, 2002, Pages 1877-1888

  Novick, J ^a   Miner, P ^b   Krause, R ^b   Glebas, K ^b   Bliesath, Harald ^b   Ligozio, G ^b   Ruegg P ^b   Lefkowitz, M ^b  

^a Charm City Research   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TEGASEROD;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ARTICLE; BLOATING; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DEFECATION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLATULENCE; HEADACHE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; PALLIATIVE THERAPY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; UPPER RESPIRATORY TRACT INFECTION;

ADULT; COLONIC DISEASES, FUNCTIONAL; CONSTIPATION; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL AGENTS; HUMAN; INDOLES; MIDDLE AGE; PATIENT SATISFACTION; PROSPECTIVE STUDIES; SEROTONIN AGONISTS; SUPPORT, NON-U.S. GOV'T; TREATMENT OUTCOME;

EID: 0036829638     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2002.01372.x     Document Type: Article

References (31)

1. Horwitz BJ, Fisher RS. The irritable bowel syndrome. N Engl J Med 2001; 344(24): 1846-50.
2. Thompson WG, Creed F, Drossman DA, et al. Functional bowel disease and functional abdominal pain. Gastroenterol Int 1992; 5: 75-91.
3. Camilleri M, Choi MG. Review article: Irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11: 3-15.
4. Camilleri M, Northcutt RA, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: A randomised, placebo controlled trial. Lancet 2000; 355: 1035-40.
5. Jailwala J, Imperiale TF, Kroenke K. Pharamacological treatment of the irritable bowel syndrome: A systematic review of randomized, controlled trials. Ann Intern Med 2000; 133: 136-47.
6. Camilleri M. Review article: Clinical evidence to support current therapies of irritable bowel syndrome. Aliment Pharmacol Ther 1999; 13((Suppl. 2): 48-53.
7. 4 receptor agonist stimulates transmitter release and activates the intestinal peristaltic reflex. Gastroenterology 1996; 110: A1075(Abstract).
8. 4 agonist, stimulates canine colonic motility and transit in vivo. Gastroenterology 1996; 110: A724(Abstract).
9. Schikowski A, Thewißen M, Mathis C, Ross H-G, Enck P. Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum. Neurogastroenterol Motil 2002; 14: 221-7.
10. Coelho AM, Rovira P, Fioramonti J, et al. Antinociceptive properties of HTF 919 (tegaserod), a 5-HT4 receptor partial agonist on colorectal distension in rats. Gastroenterology 2000; 118: 4(Suppl. 2): A835: 4393.
11. 4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001; 15: 1745-51.
12. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000; 118(3): 463-8.
13. Klein KB. Controlled treatment trials in the irritable bowel syndrome: A critique. Gastroenterology 1988; 95: 232-41.
14. Veldhuyzen van Zanten SJO, Talley NJ, Bytzer P, et al. Design of treatment trials for functional gastrointestinal disorders. Gut 1999; 45((Suppl. II): 69-77.
15. Spiller RC. Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials. Am J Med 1999; 107(5A): 91-7.
16. 4 receptor partial agonist, relieves abdominal pain and improves bowel function in irritable bowel syndrome. Aliment Pharmacol Ther 2001; 15: 1655-66.
17. Drossman DA, Thompson WG, Talley NJ, et al. Identification of sub-groups of functional gastrointestinal disorders. Gastroenterol Int 1990; 3: 359-72.
18. Harding JP, Hamm LR. Ehsanullah RS, et al. Use of a novel electronic data collection system in multicenter studies of irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11(6): 1073-6.
19. Lelkowitz M, Rueegg P, Dunger-Baldauf C, Shi Y. Validation of a global relief measure in clinical trials of irritable bowel syndrome with tegaserod. Gastroenterology 2000; 188(4)(Suppl. 2:) A145, 855.
20. Koch GG, Tangen CM, Jung JW, Amara IA. Issues for covariance analysis of dichotomous and ordered categorical data from randomized clinical trials and non-parametric strategies for addressing them. Statistics Med 1998; 17: 1863-92.
21. Cook RJ, Sacket DL. The number needed to treat: A clinically useful measure of treatment effect. Br Med J 1995; 310: 452-4.
22. Laupacis A, Sacket DL, Robert RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988; 318(26): 1728-33.
23. Schouten HJA. Simple and effective confidence intervals for the number needed to treat. Control Clin Trials 2002; 23: 100-2.
24. Thompson WG, Longstreth GF, Drossman DA, Heaton KH, Irvine EJ, Mueller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999; 45(Suppl. II): 1143-7.
25. Mayer EA, Naliboff B, Lee O, Munakata J, Chang L. Review article: Gender-related differences in functional gastrointestinal disorders. Aliment Pharmacol Ther 1999; 13(Suppl. 2): 65-9.
26. Degen LP, Phillips SF. Variability of gastrointestinal transit in healthy women and men. Gut 1996; 39(2): 299-305.
27. Farthing MJ. Irritable bowel syndrome: New pharmaceutical approaches to treatment. Baillieres Clin Gastroenterol 1999; 13: 461-71.
28. Kamm MA. Review article: The complexity of drug development for irritable bowel syndrome. Aliment Pharmacol Ther 2002; 16: 343-51.
29. Northcutt AR, Mangel AW, Hamm LR, et al. Persistent Placebo Response During a Year-long Controlled Trial of IBS Treatment. Abstract 3243, DDW 2001.
30. Thompson WG. Placebo: A review of the placebo response. Am J Gastroenterol 2000; 95: 1637-43.
31. 4 receptor partial agonist, is devoid of significant electrocardiographic side effects. Am J Gastroenterol 2002; 97(9): in press.